Skip to Content
Merck
  • Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen.

Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen.

Antimicrobial agents and chemotherapy (2011-05-18)
Santiago Ramón-García, Carol Ng, Hilary Anderson, Joseph D Chao, Xingji Zheng, Tom Pfeifer, Yossef Av-Gay, Michel Roberge, Charles J Thompson
ABSTRACT

Therapeutic options for tuberculosis (TB) are limited and notoriously ineffective despite the wide variety of potent antibiotics available for treating other bacterial infections. We investigated an approach that enables an expansion of TB therapeutic strategies by using synergistic combinations of drugs. To achieve this, we devised a high-throughput synergy screen (HTSS) of chemical libraries having known pharmaceutical properties, including thousands that are clinically approved. Spectinomycin was used to test the concept that clinically available antibiotics with limited efficacy against Mycobacterium tuberculosis might be used for TB treatment when coadministered with a synergistic partner compound used as a sensitizer. Screens using Mycobacterium smegmatis revealed many compounds in our libraries that acted synergistically with spectinomycin. Among them, several families of antimicrobial compounds, including macrolides and azoles, were also synergistic against M. tuberculosis in vitro and in a macrophage model of M. tuberculosis infection. Strikingly, each sensitizer identified for synergy with spectinomycin uniquely enhanced the activities of other clinically used antibiotics, revealing a remarkable number of unexplored synergistic drug combinations. HTSS also revealed a novel activity for bromperidol, a butyrophenone used as an antipsychotic drug, which was discovered to be bactericidal and greatly enhanced the activities of several antibiotics and drug combinations against M. tuberculosis. Our results suggest that many compounds in the currently available pharmacopoeia could be readily mobilized for TB treatment, including disease caused by multi- and extensively drug-resistant strains for which there are no effective therapies.

MATERIALS
Product Number
Brand
Product Description

Supelco
Spectinomycin dihydrochloride pentahydrate, VETRANAL®, analytical standard
Sigma-Aldrich
Spectinomycin dihydrochloride pentahydrate, potency: ≥603 μg per mg
Sigma-Aldrich
Spectinomycin dihydrochloride pentahydrate, powder, γ-irradiated
Sigma-Aldrich
Spectinomycin dihydrochloride pentahydrate, powder, BioReagent, suitable for cell culture
Bromperidol, European Pharmacopoeia (EP) Reference Standard